A review of the clinical pharmacology of methamphetamine
- PMID: 19426289
- DOI: 10.1111/j.1360-0443.2009.02564.x
A review of the clinical pharmacology of methamphetamine
Abstract
Aims: To examine the literature regarding clinical pharmacokinetics, direct effects and adverse clinical outcomes associated with methamphetamine use.
Methods: Relevant literature was identified through a PubMed search. Additional literature was obtained from relevant books and monographs.
Findings and conclusions: The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics. Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination. At higher doses used typically by illicit users (> or =50 mg), methamphetamine can produce psychosis. Its hypertensive effect can produce a number of acute and chronic cardiovascular complications. Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance. Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.
Similar articles
-
Methamphetamine and cardiovascular pathology: a review of the evidence.Addiction. 2007 Aug;102(8):1204-11. doi: 10.1111/j.1360-0443.2007.01874.x. Epub 2007 Jun 12. Addiction. 2007. PMID: 17565561 Review.
-
Clinical course and outcomes of methamphetamine-dependent adults with psychosis.J Subst Abuse Treat. 2008 Dec;35(4):445-50. doi: 10.1016/j.jsat.2007.12.004. Epub 2008 Feb 21. J Subst Abuse Treat. 2008. PMID: 18294802
-
Human pharmacology of the methamphetamine stereoisomers.Clin Pharmacol Ther. 2006 Oct;80(4):403-20. doi: 10.1016/j.clpt.2006.06.013. Clin Pharmacol Ther. 2006. PMID: 17015058 Clinical Trial.
-
[Driving under the influence of amphetamine and metamphetamine].Tidsskr Nor Laegeforen. 2009 Jan 15;129(2):105-8. doi: 10.4045/tidsskr.09.34091. Tidsskr Nor Laegeforen. 2009. PMID: 19151802 Norwegian.
-
Clinical effects and management of methamphetamine abuse.Pharmacotherapy. 2006 Aug;26(8):1148-56. doi: 10.1592/phco.26.8.1148. Pharmacotherapy. 2006. PMID: 16863490 Review.
Cited by
-
Impact of methamphetamine on infection and immunity.Front Neurosci. 2015 Jan 12;8:445. doi: 10.3389/fnins.2014.00445. eCollection 2014. Front Neurosci. 2015. PMID: 25628526 Free PMC article. Review.
-
Effects of moderate-intensity exercise on social health and physical and mental health of methamphetamine-dependent individuals: A randomized controlled trial.Front Psychiatry. 2022 Sep 23;13:997960. doi: 10.3389/fpsyt.2022.997960. eCollection 2022. Front Psychiatry. 2022. PMID: 36213929 Free PMC article.
-
Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center.J Addict Med. 2017 Jan/Feb;11(1):19-27. doi: 10.1097/ADM.0000000000000262. J Addict Med. 2017. PMID: 27649265 Free PMC article.
-
The role of the GABA system in amphetamine-type stimulant use disorders.Front Cell Neurosci. 2015 May 5;9:162. doi: 10.3389/fncel.2015.00162. eCollection 2015. Front Cell Neurosci. 2015. PMID: 25999814 Free PMC article. Review.
-
The medication violations in racehorses at Louisiana racetracks from 2016 to 2020.Vet Med Sci. 2022 Mar;8(2):553-560. doi: 10.1002/vms3.724. Epub 2022 Jan 6. Vet Med Sci. 2022. PMID: 34989156 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
